Elyssa Blissenbach will review your health history and help determine the best treatment approach for you
So, next time youre reading something thats been reviewed by someone with serious credentials, remember that professionals can be just as sloppy in their work as anyone else
47 , W556w560 (2019)
All participants had a BMI 27 kg/m, established cardiovascular disease (prior MI, stroke, or peripheral artery disease), but no diabetes, making this the largest trial of a GLP-1RA in a non-diabetic, high-risk cardiovascular cohort
This improvement occurs through multiple mechanisms: reduced aromatase activity as fat mass decreases, improved insulin sensitivity, decreased inflammatory cytokines, and restoration of normal hypothalamic-pituitary function
Phase 2b completed in T2D) Status: Investigational not approved by FDA or EMA Heres what makes it different from everything else on the market and in the pipeline: - Semaglutide (Ozempic/Wegovy/Rybelsus): GLP-1 only - Tirzepatide (Mounjaro/Zepbound): GLP-1 + GIP - Retatrutide (investigational): GLP-1 + GIP + Glucagon - Amycretin : GLP-1 + Amylin Different receptor pairing